Literature DB >> 7107476

Sympathetic and parasympathetic cardiac control in athletes and nonathletes at rest.

P G Katona, M McLean, D H Dighton, A Guz.   

Abstract

A simple model to characterize sympathetic and parasympathetic effects on heart rate (R) was tested during rest in 10 nonathletes and 8 world-class oarsmen. The model states that R = mnR0, where R0 is the intrinsic cardiac rate, and m and n depend only on sympathetic and parasympathetic activity, respectively. The multipliers, m and n, were determined by dual pharmacological blockade in two sessions under similar conditions, but in one session propranolol and in the other atropine was given first. In agreement with the model, when corrections were made for atropine-induced blood pressure changes, m and n did not depend on which blocking agent was administered first. In athletes the control heart rate [55 +/- 3.3 (SD) beats/min] and R0 (81 +/- 8.3 beats/min) were lower than in nonathletes (62 +/- 6.0, P less than 0.01 and 102 +/- 11, P less than 0.001, respectively). The sympathetic multiplier, m, was similar (1.18 +/- 0.06 vs. 1.20 +/- 0.05, P greater than 0.4) in the two groups, but n, the parasympathetic multiplier, was closer to 1 in the athletes (0.57 +/- 0.03 vs. 0.51 +/- 0.05, P less than 0.01). We conclude that the model is suitable for the quantitative study of sympathetic/parasympathetic heart rate control in humans, and that the lower resting heart rate in oarsmen is solely due to a reduction in intrinsic cardiac rate, and not to an increase in parasympathetic tone.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107476     DOI: 10.1152/jappl.1982.52.6.1652

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  53 in total

Review 1.  Evidence and possible mechanisms of altered maximum heart rate with endurance training and tapering.

Authors:  G S Zavorsky
Journal:  Sports Med       Date:  2000-01       Impact factor: 11.136

Review 2.  Effect of endurance exercise on autonomic control of heart rate.

Authors:  James B Carter; Eric W Banister; Andrew P Blaber
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

3.  Estimation of VO2max from the ratio between HRmax and HRrest--the Heart Rate Ratio Method.

Authors:  Niels Uth; Henrik Sørensen; Kristian Overgaard; Preben K Pedersen
Journal:  Eur J Appl Physiol       Date:  2003-11-18       Impact factor: 3.078

Review 4.  Heart rate monitoring: applications and limitations.

Authors:  Juul Achten; Asker E Jeukendrup
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

5.  Relation between physical exertion and heart rate variability characteristics in professional cyclists during the Tour of Spain.

Authors:  C P Earnest; R Jurca; T S Church; J L Chicharro; J Hoyos; A Lucia
Journal:  Br J Sports Med       Date:  2004-10       Impact factor: 13.800

6.  Heart rate variability and its relation to prefrontal cognitive function: the effects of training and detraining.

Authors:  Anita Lill Hansen; Bjørn Helge Johnsen; John J Sollers; Kjetil Stenvik; Julian F Thayer
Journal:  Eur J Appl Physiol       Date:  2004-12       Impact factor: 3.078

7.  Autonomic nervous control of the heart rate response to dynamic incremental exercise: evaluation of the Rosenblueth-Simeone model.

Authors:  J P Ribeiro; J M Ibáñez; R Stein
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1991

8.  Beta-adrenergic receptor desensitization in man: insight into post-exercise attenuation of cardiac function.

Authors:  Emma Hart; Ellen Dawson; Peter Rasmussen; Keith George; Niels H Secher; Greg Whyte; Rob Shave
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

9.  Respiratory sinus arrhythmia alteration following training in endurance athletes.

Authors:  R E De Meersman
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1992

Review 10.  Heart rate variability in athletes.

Authors:  André E Aubert; Bert Seps; Frank Beckers
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.